Aptevo Therapeutics, Inc. (APVO)

Aptevo Therapeutics' stock experienced volatility with several key events. The company secured a $60 million equity line of credit. A 1-for-18 reverse stock split was implemented on December 29, 2025. Preliminary Phase 1b/2 RAINIER data for mipletamig was presented at ASH 2025. Director Grant Grady III purchased 13,513 shares. Aptevo debuted its first trispecific antibody candidate, APVO451. Q3 2025 financial results showed an 89% remission rate among AML patients treated with mipletamig combinations. The stock plummeted to a new 52-week low of $1.32. Mipletamig delivered a 100% remission rate in Cohort 3 of the RAINIER trial. Aptevo reported Q2 2025 financial results, with mipletamig achieving an 85% remission rate in frontline AML patients. The company initiated its Phase 1b/2 dose optimization trial, RAINIER.

Aptevo Therapeutics, as a clinical-stage biotechnology company, focuses on R&D rather than commercial sales, and is primarily funded by equity financing. Therefore, traditional demand seasonality does not apply. The company's progress is driven by clinical trial outcomes, regulatory milestones, and drug candidate advancement, which are not seasonal.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapeutic candidates for cancer treatment. The company uses its ADAPTIR™ and ADAPTIR-FLEX™ platforms to create antibody candidates that enhance the immune system against cancer cells. Key product candidates include Mipletamig (APVO436) for AML, ALG.APV-527 for solid tumors, APVO603, APVO711, APVO442 for prostate cancer, APVO451 and APVO452 for solid tumors, and APVO455 for solid tumors. Aptevo previously sold commercial hyperimmune products and IXINITY, but now focuses on its immuno-oncology pipeline.

Aptevo Therapeutics Inc. is headquartered in Seattle, Washington, and its operations are primarily within the United States. Specific details about international operations or revenue distribution are not publicly available.

Aptevo Therapeutics has a generally positive news sentiment score of 0.60. Positive events include promising clinical trial results for mipletamig, pipeline expansion with new trispecific antibody candidates, financial stability measures through equity lines of credit, and insider confidence. Negative impacts include reverse stock splits, a significant stock price decline, financial challenges with negative earnings and high leverage, and high stock volatility.

Aptevo Therapeutics' ownership is mainly public companies and retail investors, holding approximately 95.28% to 98.90% of the stock. Institutional investors hold 1.01% to 8.06%, and insiders hold about 0.08% to 0.12%. Major institutional shareholders include Point72 Asset Management, L.P., DRW Securities, LLC, and Virtu Financial LLC. Grant Grady III, a director, is a significant individual investor.